ArticleClinical kidney journal2025
Relationship between magnesium intake and decline in kidney function, incident chronic kidney disease and incident cardiovascular disease.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Background and hypothesis: Higher magnesium (Mg) intake is associated with a lower risk of stroke, heart failure and mortality, while there are limited data with kidney disease outcomes. We hypothesized that higher dietary Mg intake would be associated with a lower incidence of cardiovascular disease (CVD), chronic kidney disease (CKD) and kidney function decline. Methods: The Health, Aging, and Body Composition Study is an observational cohort of 3075 community-dwelling older adults. Dietary Mg intake was estimated using validated dietary surveys. Kidney outcomes included ≥30% decline in estimated glomerular filtration rate (eGFR) cystatin or incident CKD, which was defined as a subsequent eGFR <60 mL/min/1.73 m Results: After excluding missing data, 2682 individuals were available for analysis. The median daily dietary Mg intake was 278 mg/day (11.4 mmol/day) (25th-75th percentile: 214-350 mg/day). Among 1871 individuals without baseline CKD, 522 developed incident CKD, while within the whole cohort, 394 (14.7%) had a ≥30% decline in eGFR over 10 years. Higher Mg intake was independently associated with lower risk of 30% eGFR decline [incidence rate ratio (IRR) per standard deviation (SD) higher Mg intake = 0.79 (95% confidence interval 0.66, 0.93)] and with a lower risk of incident CKD [IRR per SD higher Mg intake = 0.84 (95% confidence interval 0.73, 0.96)]. Among 1968 individuals without baseline CVD, 634 developed incident CVD. There was no association between Mg intake and overall incident CVD [adjusted hazard ratio 0.98 (95% confidence interval 0.85, 1.13)]. Conclusions: Higher Mg intake was associated with a lower risk of 30% decline in eGFR and incident CKD but not with incident CVD in a large cohort of older adults. The impact of Mg supplementation on kidney outcomes warrants further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.